Botulinum toxin type A as an adjuvant therapeutic option for axillary Hailey–Hailey disease

The modern view on the application of botulinum toxin type A for the off-label use in neurology and foreign experience analysis are presented. The «off-label» category referred to any prescription of a medication in case of using it for unregistered indications, with product instruction violation or in the presence of contraindications including age restrictions. The sources of information about medicines were the leaflets of manufacturers of medicines and the State Register of Medicines. It is well known that Botulinum toxin type A is a good therapeutic option for treating children with cerebral palsy. Increased efficacy of regularly repeated cycles with Onabotulinumtoxin A in medication-overuse headache patients beyond the first year of treatment. Botulinum toxin type A is effective in the management of sialorrhea. Botulinum toxin type A is a safe and effective treatment for primary axillary hyperhidrosis and produces high levels of patient satisfaction. Facing depression with botulinum toxin: positive effects on mood have been observed in subjects who underwent treatment of glabellar frown lines with botulinum toxin and, in an open case series, depression remitted or improved after such a treatment. Botox injection significantly improved foot dystonia, pain and lower limb functional outcomes in patients with Parkinson’s disease with deep brain stimulation. The paper describes the problems associated with the lack of clinical data about the possibility of using botulinum toxin type A in different conditions, emphasizes the need to organize clinical trials and educational programs for neurologists as well as more active implementation of protocols for the treatment of patients.

Download Full-text

Botulinum toxin type A in chronic neuropathic pain in refractory leprosy

Arquivos de Neuro-Psiquiatria ◽

10.1590/0004-282x20190053 ◽

2019 ◽

Vol 77 (5) ◽

pp. 346-351 ◽

Cited By ~ 1

Author(s):

Emanuel de Jesus Soares de Sousa ◽

Gustavo Celeira de Sousa ◽

Vitor Ferreira Baia ◽

Danusa Neves Somensi ◽

Marília Brasil Xavier

Keyword(s):

Quality Of Life ◽

Neuropathic Pain ◽

Botulinum Toxin ◽

Therapeutic Option ◽

Botulinum Toxin Type A ◽

Type A ◽

Botulinum Toxin Type ◽

Chronic Neuropathic Pain ◽

Specific Protocol

ABSTRACT Neuropathic pain is a chronic syndrome that is difficult to treat and often affects patients with leprosy. Recommended treatment includes the the use of analgesic drugs, codeine, tricyclic antidepressants, neuroleptics, anticonvulsants and thalidomide, but without consensus on uniform dose and fully satisfactory results. Objective: To analyze botulinum toxin type A (BoNT-A) effectiveness in treatment of chronic neuropathic pain in refractory leprous patients, as well as evaluate and compare the quality of life of patients before and after using the medication. Methods: We used a specific protocol including clinical, demographic, DN4 protocol, analogue scale (VAS), sensory evaluation and evaluation of the WHOQOL-BREF. Therapeutic intervention was performed with BOTOX® BTX-A 100U administered subcutaneously. Fifteen patients were evaluated on days 0, 10 and 60. Results: Patients on VAS showed pain between 5 and 10, in one case there was complete pain relief in 60 days, while others showed improvement in the first week with the return of symptoms with less intensity after this period. WHOQOL-BREF's domains Quality of Life and Physical to have a significant increase in QOL. Conclusion: BoNT-A proved to be a good therapeutic option in relieving pain with improved quality of life for these patients.

Download Full-text

Poster 234: Injection of Botulinum Toxin Type A as a Therapeutic Option for Bladder Preservation in Patients With Severe Neurogenic Detrusor Overactivity

PM&R ◽

10.1016/j.pmrj.2010.07.267 ◽

2010 ◽

Vol 2 ◽

pp. S106-S106

Author(s):

Taisha Williams

Keyword(s):

Botulinum Toxin ◽

Detrusor Overactivity ◽

Therapeutic Option ◽

Botulinum Toxin Type A ◽

Type A ◽

Botulinum Toxin Type ◽

Neurogenic Detrusor Overactivity ◽

Bladder Preservation

Download Full-text

Use of botulinum toxin type a in temporomandibular disorder

RGO - Revista Gaúcha de Odontologia ◽

10.1590/1981-863720170002000093144 ◽

2017 ◽

Vol 65 (2) ◽

pp. 151-155

Author(s):

Mary Akemy Uehara HUAMANI ◽

Luciano Artioli MOREIRA ◽

Ney Soares de ARAÚJO ◽

Marcelo Henrique NAPIMOGA ◽

José Luiz Cintra JUNQUEIRA ◽

...

Keyword(s):

Botulinum Toxin ◽

Therapeutic Option ◽

Temporomandibular Disorder ◽

Botulinum Toxin Type A ◽

Type A ◽

Botulinum Toxin Type ◽

Temporal Muscle ◽

Clinical Scenarios ◽

Patient Reported ◽

Muscles Of Mastication

ABSTRACT Temporomandibular disorder (TMD) may be defined as a set of clinical scenarios involving the masticatory muscles, the temporomandibular joint (TMJ) and associated structures. Currently, 40 to 75% of the population has some sign of temporomandibular disorder, mainly pain located in the muscles of mastication in the pre-auricular region. The present clinical case was diagnosed as muscle temporomandibular disorder secondary to parafunction, as well as muscle hyperactivity due to surgical displacement of the left temporal muscle on two occasions, one for placement of aneurysm clips and the other for tumor excision from the supraorbital region on the left side. The patient sought medical and dental attention for 10 years due to constant headaches, tiredness and pain in the cheeks. The patient tried numerous bite-guards and pharmacological therapies to no avail. The American Academy of Orofacial Pain Questionnaire was applied combined with the Criteria for Research and Diagnostics (DRC) and a decision was made to use botulinum toxin type A in the masseter and temporalis muscles. An analog pain scale was applied over 90 days. Three days following the application of botulinum toxin type A, the patient reported a significant improvement with complete resolution of pain (level 0) after 90 days. At 12 weeks from starting treatment, facial muscle physiotherapy was introduced to strengthen the muscles of mastication and the patient remained pain-free, which allowed the preparation and adaptation of a snap-on prosthetic appliance. In conclusion, the use of botulinum toxin in patients with temporomandibular disorder should be considered as a viable therapeutic option.

Download Full-text

Type A Botulinum Toxin as Complement to Gingivoplasty in the Treatment of Gummy Smile. Case Report

Universitas Odontologica ◽

10.11144/javeriana.uo37-78.tabt ◽

2018 ◽

Vol 37 (78) ◽

Author(s):

Irineu Gregnanin Pedron

Keyword(s):

Botulinum Toxin ◽

Dental Treatment ◽

Therapeutic Option ◽

Botulinum Toxin Type A ◽

Type A ◽

Botulinum Toxin Type ◽

Self Esteem ◽

Gingival Tissue ◽

Gummy Smile

Background: The pursuit of esthetic excellence has become a major goal in the dental treatment. Gummy smile is one of the complaints of the patients, since such a situation can influence self-esteem and social relationships. The beauty of the smile is not only constituted by the shape, position and size of the teeth, but also based on the characteristics of the gingival tissue and conformation of the lips, which should be as harmonious as teeth. The development of new more conservative techniques may provide a better therapeutic option than surgical procedures, such as the application of botulinum toxin, in the treatment of gummy smile. Purpose: to present the case of a patient who presented dentogingival discrepancy caused by gingival overgrowth and gummy smile, treated by gingivoplasty and complemented by application of botulinum toxin. Description of the case: The gingivoplasty was performed followed by the application of botulinum toxin type A. Results: The gingivoplasty resulted of the improvement of gingival arches and the application of botulinum toxin promoted the dehiscence of upper lip, reducing the gingival exposure. Conclusions: The application of botulinum toxin, associated with gingivoplasty, is an important tool at the management of gummy smile, optimizing smile harmony and achieving improved self-esteem and quality of life.

Download Full-text